Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
RNWWW ReNew Energy Global Equity Warrant Exp 23rd Aug 2026 *W EXP 08/23/2026
RVPH Reviva Pharmaceuticals Holdings, Inc.
TPR Tapestry Inc
BGRY Berkshire Grey Inc
BKNG Booking Holdings Inc
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$173.25
Day's Change
-3.10 (-1.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
178.74
Day's Low
172.40
Volume
(Below Average)
Volume:
2,821,351

10-day average volume:
3,521,279
2,821,351

Company Profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Valuation Ratios

Price/Earnings (TTM)
6.26x
Price/Sales (TTM)
3.11x
Price/Book (MRQ)
3.73x
Price/Cash Flow (TTM)
5.50x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

January 2023
Current Month
14.0M
Previous Month
14.0M
Percent of Float
4.05%
Days to Cover
4.1644 Days

Share Information

MRNA is in a share class of common stock
Float
346.9M
Shares Outstanding
384.2M
Institutions Holding Shares
1,356
64.09%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Noubar B. Afeyan
  • Stephen HogePres.
  • Stephane BancelCEO
  • James M. MockCFO
  • Juan AndresCorp.Exec.

Address

Insider Trading

During the most recent quarter, 3M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.